Literature DB >> 22350143

Puerariae flos alleviates metabolic diseases in Western diet-loaded, spontaneously obese type 2 diabetic model mice.

Koshi Kubo1, Tsutomu Shimada, Rei Onishi, Masahito Tsubata, Tomoyasu Kamiya, Rika Nagamine, Seiichi Iizuka, Yoshimichi Sai, Sakae Amagaya, Masaki Aburada, Ken-ichi Miyamoto.   

Abstract

Puerariae flos extract (PFE) has been reported to have many effects, including preventing the development of hangovers, liver protective effects, and an estrogenic effect. In addition, some papers reported that PFE is effective against metabolic diseases, with hypolipidemic and hypoglycemic effects. However, the mechanism underlying such effects remains unclear. For the purpose of clarifying the effect of PFE on metabolic diseases related to the accumulation of visceral fat and to determine the mechanism of such action, TSOD mice, a multifactorial genetic disease animal model that spontaneously develops various metabolic diseases such as obesity and type 2 diabetes, were given a Western diet (WTD) as an environmental factor to prepare a disease model (TSOD-WTD). When TSOD mice were loaded with WTD, it was confirmed that metabolic diseases such as obesity and abnormal glucose/lipid metabolism are aggravated. In contrast, PFE treatment to TSOD-WTD mice was shown to suppress body weight gain and visceral fat accumulation, alleviated the abnormal glucose tolerance and hyperinsulinemia, as well as causing an increase in blood adiponectin. Furthermore, the suppression of liver enlargement was observed in PFE-treated mice, with suppression of fatty degeneration and anti-inflammatory effect. In addition, to clarify the mechanism of the hyperlipidemia-alleviating effects in the liver, we investigated the effect of PFE on the expression of genes involved in cholesterol homeostasis. PFE was associated with a significant increase in gene expression for cholesterol synthesis rate-limiting enzyme HMG-CoA reductase, cholesterol catabolization enzyme Cyp7A1, bile salt export pump adenosine triphosphate-binding cassette transporter B11, and low-density lipoprotein receptor involved in cholesterol uptake. The above results suggest that PFE acts to alleviate the effects of various metabolic diseases based on the accumulation of visceral adipose tissue, including obesity, diabetes, and hyperlipidemia, with the promotion of catabolization/excretion of cholesterol in the liver being a key mechanism of action.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22350143     DOI: 10.1007/s11418-012-0629-z

Source DB:  PubMed          Journal:  J Nat Med        ISSN: 1340-3443            Impact factor:   2.343


  27 in total

1.  A dominant negative peroxisome proliferator-activated receptor-gamma knock-in mouse exhibits features of the metabolic syndrome.

Authors:  Bethany D Freedman; Eun-Jig Lee; Youngkyu Park; J Larry Jameson
Journal:  J Biol Chem       Date:  2005-02-15       Impact factor: 5.157

2.  Hypoglycemic and hypolipidemic effects of tectorigenin and kaikasaponin III in the streptozotocin-lnduced diabetic rat and their antioxidant activity in vitro.

Authors:  K T Lee; I C Sohn; D H Kim; J W Choi; S H Kwon; H J Park
Journal:  Arch Pharm Res       Date:  2000-10       Impact factor: 4.946

3.  Carnosic acid prevents obesity and hepatic steatosis in ob/ob mice.

Authors:  Ting Wang; Yasuhiro Takikawa; Takumi Satoh; Yoshichika Yoshioka; Kunio Kosaka; Yoshinori Tatemichi; Kazuyuki Suzuki
Journal:  Hepatol Res       Date:  2011-01       Impact factor: 4.288

4.  Metabolic disease prevention and suppression of fat accumulation by Salacia reticulata.

Authors:  Tsutomu Shimada; Eiichi Nagai; Yukiko Harasawa; Tomoko Akase; Takashi Aburada; Seiichi Iizuka; Ken-ichi Miyamoto; Masaki Aburada
Journal:  J Nat Med       Date:  2010-03-12       Impact factor: 2.343

5.  Hepatoprotective effect of tectoridin and tectorigenin on tert-butyl hyperoxide-induced liver injury.

Authors:  Hae-Ung Lee; Eun-Ah Bae; Dong-Hyun Kim
Journal:  J Pharmacol Sci       Date:  2005-04-09       Impact factor: 3.337

6.  Flavangenol (pine bark extract) and its major component procyanidin B1 enhance fatty acid oxidation in fat-loaded models.

Authors:  Tsutomu Shimada; Daisuke Tokuhara; Masahito Tsubata; Tomoyasu Kamiya; Mayu Kamiya-Sameshima; Rika Nagamine; Kinya Takagaki; Yoshimichi Sai; Ken-Ichi Miyamoto; Masaki Aburada
Journal:  Eur J Pharmacol       Date:  2011-12-29       Impact factor: 4.432

7.  Tectoridin, an isoflavone glycoside from the flower of Pueraria lobata, prevents acute ethanol-induced liver steatosis in mice.

Authors:  Yu Xiong; Yuqing Yang; Jin Yang; Hongyan Chai; Ying Li; Jing Yang; Ziming Jia; Zhengrong Wang
Journal:  Toxicology       Date:  2010-07-15       Impact factor: 4.221

8.  Effect of kaikasaponin III obtained from Pueraria thunbergiana flowers on serum and hepatic lipid peroxides and tissue factor activity in the streptozotocin-induced diabetic rat.

Authors:  Jongwon Choi; Myung-Hee Shin; Kun-Young Park; Kyung-Tae Lee; Hyun-Ju Jung; Myung-Sun Lee; Hee-Juhn Park
Journal:  J Med Food       Date:  2004       Impact factor: 2.786

9.  Beta-glucuronidase inhibitor tectorigenin isolated from the flower of Pueraria thunbergiana protects carbon tetrachloride-induced liver injury.

Authors:  Hae-Woong Lee; Min-Kyung Choo; Eun-Ah Bae; Dong-Hyun Kim
Journal:  Liver Int       Date:  2003-08       Impact factor: 5.828

10.  Preventive effect of pine bark extract (flavangenol) on metabolic disease in Western diet-loaded tsumura suzuki obese diabetes mice.

Authors:  Tsutomu Shimada; Mitsutaka Kosugi; Daisuke Tokuhara; Masahito Tsubata; Tomoyasu Kamiya; Mayu Sameshima; Rika Nagamine; Kinya Takagaki; Ken-Ichi Miyamoto; Masaki Aburada
Journal:  Evid Based Complement Alternat Med       Date:  2011-03-17       Impact factor: 2.629

View more
  1 in total

1.  Flos puerariae ameliorates the intestinal inflammation of Drosophila via modulating the Nrf2/Keap1, JAK-STAT and Wnt signaling.

Authors:  Shipei Yang; Xu Li; Minghui Xiu; Yuting Dai; Shengfang Wan; Yan Shi; Yongqi Liu; Jianzheng He
Journal:  Front Pharmacol       Date:  2022-08-17       Impact factor: 5.988

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.